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SETTING: Thyolo district, Malawi.
OBJECTIVES: To report on 1) case fatality among
human immunodeﬁciency virus (HIV) positive tubercu-
losis (TB) patients while on anti-tuberculosis treatment
and 2) whether antiretroviral treatment (ART) initiated
during the continuation phase of TB treatment reduces
case fatality.
DESIGN: Retrospective cohort analysis.
METHODS: Comparative analysis of treatment outcomes
for TB patients registered between January and Decem-
ber 2004.
RESULTS: Of 983 newly registered TB patients receiv-
ing diagnostic HIV testing, 658 (67%) were HIV-positive.
A total of 132 (20%) patients died during the 8-month
course of anti-tuberculosis treatment, of whom 82 (62%)
died within the ﬁrst 2 months of treatment when ART
was not provided (cumulative incidence 3.0, 95%CI 2.5–
3.6 per 100 person-years). A total of 576 TB patients
started the continuation phase of anti-tuberculosis treat-
ment, 180 (31%) of whom were started on ART. The
case-fatality rate per 100 person-years was not signiﬁ-
cantly different for patients on ART (1.0, 95%CI 0.6–1.7)
and those without ART (1.2, 95%CI 0.9–1.7, adjusted
hazard ratio 0.86, 95%CI 0.4–1.6, P   0.6)
CONCLUSIONS: ART provided in the continuation phase
of TB treatment does not have a signiﬁcant impact on
reducing case fatality. Reasons for this and possible mea-
sures to reduce high case fatality in the initial phase of
TB treatment are discussed.
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HUMAN IMMUNODEFICIENCY VIRUS (HIV)
positive patients with tuberculosis (TB) in sub-
Saharan Africa have high death rates during and fol-
lowing anti-tuberculosis treatment.1–3 Case-fatality
rates (deaths during treatment) have a negative im-
pact on cure rates and challenge the credibility of TB
control programmes amongst patients, health care
staff and the community. Effective adjunctive inter-
ventions to reduce case-fatality rates in sub-Saharan
Africa are urgently needed.
HIV-positive patients with TB in our setting are all
potentially eligible for antiretroviral treatment (ART),
either because they are in World Health Organization
(WHO) Clinical Stage 3 (pulmonary TB, PTB) or in
WHO Clinical Stage 4 (extra-pulmonary TB, EPTB).4
The WHO recommends that where CD4 testing ser-
vices are not yet available (or feasible), all individuals
classiﬁed as WHO stage 3 or 4 could be considered el-
igible for ART.
In principle, HIV-positive TB patients should ben-
eﬁt from ART, with a reduction in HIV-related case
fatality and episodes of recurrent TB. Reports on small
numbers of patients treated in Asian countries, such
as Taiwan5 and Thailand,6 point to good overall out-
comes for HIV-positive TB patients treated with ART.
To our knowledge, there have been no reports on
the impact on case-fatality rates in HIV-infected TB
patients treated with ART in the routine health sys-
tem in sub-Saharan Africa, where these rates are among
the highest in the world.
Every year, Thyolo District, in rural Malawi, regis-
ters a large number of HIV-positive TB patients who are
all systematically offered ART. A proportion of these
individuals accept the offer during anti-tuberculosis
treatment while others do not, thus allowing an ob-
servation of death rates between the two cohorts.
Under routine conditions of health service delivery in
this district, we report on 1) case-fatality rates among
HIV-positive TB patients while on anti-tuberculosis
treatment and 2) whether ART initiated during the
continuation phase of anti-tuberculosis treatment re-
duces case fatality.
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METHODS
Design
The study was a retrospective analysis of standard-
ised anti-tuberculosis treatment outcomes in HIV-
positive TB patients registered between 1 January and
31 December 2004 who were further divided into
those who received ART during the continuation
phase of treatment and those who did not choose
ART.
Study setting and management of TB
The study was conducted in Thyolo District, a rural
region of southern Malawi with a population of
about 550000. The great majority of inhabitants in this
district are farmers. The main public hospital in the
district (Thyolo Hospital), which registers and treats
the majority of TB patients, was involved in the study.
TB patients are diagnosed, registered and treated
according to national guidelines, using a standardised
approach7 and following WHO guidelines.8 New
patients are treated with a 2-month initial phase of
rifampicin (RMP), isoniazid (INH) and pyrazinamide
(with additional ethambutol [EMB] for sputum smear-
positive patients), followed by a 6-month continua-
tion phase of INH and EMB. Drugs and investiga-
tions for TB are free of charge and, since early 1999,
all TB patients undergo diagnostic counselling and
HIV testing. HIV-positive patients are managed for
opportunistic infections and offered cotrimoxazole
preventive treatment (CPT), provided there are no
contraindications.9
ART for TB patients
The ﬁrst-line ART regimen in Malawi is a ﬁxed-dose
combination of stavudine (d4T), lamivudine (3TC)
and nevirapine (NVP). In case of side effects, zidovu-
dine (AZT) and efavirenz (EFV) are alternatives to d4T
and NVP, respectively. ART for HIV-positive TB pa-
tients is deferred until the continuation phase of anti-
tuberculosis treatment (2 months after the start of TB
treatment) because of concerns about pill burden, im-
mune reconstitution syndrome in patients not yet sta-
bilised on anti-tuberculosis treatment and drug-drug
interactions between RMP and NVP.10
Once the patient has been started on the continua-
tion phase of anti-tuberculosis treatment (INH and
EMB), the patient is eligible to start ART. TB patients
who are started on ART are followed up monthly,
and attend the TB clinic for anti-tuberculosis medica-
tion and a separate clinic for ART drugs. ART was
started in Thyolo in April 2003 and is offered free of
charge.
Study population, data collection and 
statistical analysis
The study included all newly diagnosed HIV-positive
TB patients registered between 1 January and 31 De-
cember 2004. Only TB patients offered HIV testing
for the ﬁrst time following a diagnosis of active TB
were included in the study. Patients who were on
ART and were diagnosed with TB thereafter were not
included in the analysis. The counselling register, dis-
trict TB register, TB patient cards, ART Patient Mas-
ter Cards and ART Register11 were reviewed to gather
information on demography, HIV status, ART uptake
and outcomes of anti-tuberculosis treatment. The cu-
mulative number of deaths that occurred during the
entire course of anti-tuberculosis treatment among
HIV-positive TB patients was determined. All deaths
that occurred during the ﬁrst 2 months of the initial
phase of anti-tuberculosis treatment were then ex-
cluded, and the outcomes between those who chose
to be initiated on ART and those who chose not to be
initiated on ART while in the continuation phase of
anti-tuberculosis treatment were compared.
Thyolo has a well-developed network of community
volunteers and nurses who ensure consistent follow-up,
including home visits for non-reporting patients. Re-
liable ascertainment of deaths and other treatment
outcomes was thus possible, thereby avoiding mis-
classiﬁcations, in particular case fatality as default.
Differences between groups were compared using
the  2 test for categorical variables or the Student’s t-
test for continuous variables. Crude relative risks and
hazard ratios (HR) (per 100 person-years [py] of fol-
low-up) were used to compare death rates in the in-
tervention and control groups. HRs were adjusted
using a Cox regression model. Survival estimates were
determined using the Kaplan-Meier method and com-
pared using the Cox-Mantel (log-rank) test. The level
of signiﬁcance was set at P   0.05, and 95% conﬁ-
dence intervals (CI) were used throughout. Data were
analysed using STATA 8.2 software (Stata Corpora-
tion, College Station, TX, USA).
Ethical approval
General measures are provided in the Thyolo ART
facility to ensure patient conﬁdentiality, consent for
HIV testing, and counselling and support for those
who receive a positive HIV test result. The Malawi
National Health Science Research Committee pro-
vides general oversight and approval for the collec-
tion and use of routine programmatic data for moni-
toring and evaluation, and does not require formal
submission for ethical approval for the type of study
conducted in this paper.
RESULTS
Characteristics of the study population
A total of 983 new TB patients were registered during
the study period, of whom 658 (67%) were found to
be HIV-positive. This included 270 (41%) men and
388 women, with a mean age of 33 years. There were
297 (45%) cases of smear-positive PTB, 203 (31%)850 The International Journal of Tuberculosis and Lung Disease
smear-negative PTB and 158 (24%) EPTB cases. A
total of 401 (61%) HIV-positive TB patients were re-
ceiving CPT, usually started within 1 week of com-
mencement of anti-tuberculosis treatment. Of the 658
HIV-positive TB patients, 576 (88%) completed the
initial 2-month phase of anti-tuberculosis treatment,
and all were offered ART. One hundred and eighty
(31%) of these individuals accepted and were started
on ART (Figure 1). ART was started a median of 88
days (inter-quartile range 66–125 days) after initia-
tion of anti-tuberculosis treatment.
Deaths among HIV-positive TB patients
A total of 132 (20%) deaths occurred among HIV-
positive TB patients during the 8-month course of
anti-tuberculosis treatment. The cumulative incidence
of death among HIV-positive TB patients, whether
they received ART or not, during the 8-month period
of treatment was 3.0 (95%CI 2.5–3.6) per 100 py of
follow-up (Figure 2). Eighty-two (62%) deaths oc-
curred during the ﬁrst 2 months of treatment before
ART was offered to patients.
Characteristics and death rates in relation to ART
The Table shows the characteristics and anti-tuber-
culosis treatment outcomes (n   576) in patients started
on ART and those not started on ART, after exclud-
ing the 82 deaths that occurred during the ﬁrst 2
months of anti-tuberculosis treatment when patients
were not offered ART. Characteristics and standard-
ised end of treatment outcomes were not signiﬁcantly
different between those who started ART and those
who did not. The case-fatality rate per 100 py among
those who accepted ART (1.0, 95%CI 0.6–1.7) was
not signiﬁcantly different from that of patients who
Figure 1 Deaths and acceptance of ART among HIV-positive
TB patients in Thyolo, Malawi. *ART is initiated only after patients
have completed their initial 2-month phase of anti-tuberculosis
treatment. ART   antiretroviral treatment; HIV   human immuno-
deﬁciency virus; TB   tuberculosis.
Figure 2 Cumulative incidence of death among HIV-positive
TB patients during anti-tuberculosis treatment, Thyolo, Malawi.
HIV   human immunodeﬁciency virus; TB   tuberculosis.
Table Characteristics and treatment outcomes of TB patients 
who started the continuation phase of anti-tuberculosis 
treatment, Thyolo, Malawi (n   576)*
Variable
Accepted
ART
n (%)
Did not
accept ART
n (%) P value†
Total (N   576) 180 (31) 396 (69) —
Sex
Male 67 (37) 172 (43) 0.4
Female 113 (63) 224 (57) 0.3
Age, years, mean (range) 32 (2–74) 33 (1–74) 0.9
Type of TB 
Smear-positive PTB 89 (49) 177 (45) 0.4
Smear-negative PTB 54 (30) 126 (32) 0.9
EPTB 37 (21) 93 (24) 0.5
Treatment outcomes
Death
All TB types 14 (7) 36 (9) 0.8
Smear-positive PTB 8 (9) 12 (7) 0.8
Smear-negative PTB 5 (9) 13 (10) 0.7
EPTB 1 (3) 11 (12) 0.2
Treatment success‡
All TB types 161 (89) 348 (87) 0.2
Smear-positive PTB 79 (89) 162 (92) 0.6
Smear-negative PTB 47 (87) 107 (85) 0.8
EPTB 35 (95) 79 (85) 0.8
Other outcomes§
All TB types 5 (3) 12 (3) 0.6
Smear-positive PTB 2 (2) 3 (2) 0.5
Smear-negative PTB 2 (4) 6 (5) 0.9
EPTB 1 (3) 3 (3) 0.8
*Deaths that occurred during the ﬁrst 2 months of anti-tuberculosis treat-
ment (initial phase) were excluded.
†P value based on  2 test.
‡Treatment success includes treatment completed with negative smears
(cured) and treatment completed with no smears done.
§Other outcomes includes loss to follow-up (n   2), transfers out to another
registration facility and outcome not reported (n   7) and outcomes un-
known (n   8).
TB   tuberculosis; ART   antiretroviral treatment; PTB   pulmonary tubercu-
losis; EPTB   extra-pulmonary tuberculosis.ART in TB patients 851
did not accept ART (1.2, 95%CI 0.9–1.7). The crude
HRs for death comparing those with and without
ART was 0.83 (95%CI 0.5–1.5, P   0.5). After ad-
justment for type of TB, sex and age, this remained
non-signiﬁcant (0.86, 95%CI 0.4–1.6, P   0.6). Fig-
ure 3 shows the probability of survival in patients on
ART and patients not on ART during the continua-
tion phase of anti-tuberculosis treatment.
DISCUSSION
This study shows that about six of every 10 deaths
among HIV-positive TB patients occur very early (within
the ﬁrst 2 months) in the course of anti-tuberculosis
treatment, and that ART introduced after this period
has no signiﬁcant impact on case-fatality rates.
There are a number of possible explanations for
the limited effect observed with ART in routine set-
tings. First, as the great majority of deaths occurred
during the initial phase of anti-tuberculosis treatment
and ART is only introduced in the continuation phase,
the critical period when most deaths occur is simply
missed. Second, it is possible that patients who die in
the ﬁrst 2 months are those with HIV infection and se-
vere immunodeﬁciency (low CD4 counts). Survivors
who start the continuation phase of anti-tuberculosis
treatment are therefore those with less severe immuno-
deﬁciency (healthy cohort effect), in whom ART is
likely to have less impact in reducing case-fatality
rates in the presence of both anti-tuberculosis treat-
ment and CPT, as it takes time for ART to result in
a signiﬁcant increase in CD4-lymphocyte counts.
Third, acceptance rates of CPT were relatively high,
and as this intervention alone has a signiﬁcant effect
in reducing case fatality,9 it might have reduced the
additional effect of ART during the course of anti-
tuberculosis treatment. Fourth, we compared case-
fatality rates and survival over a relatively short pe-
riod of anti-tuberculosis treatment. The longer term
survival beneﬁt of ART is well known,12–14 and in
Malawi it has been shown that fewer than 20% of HIV-
positive TB patients remain alive 7 years after being
diagnosed with TB.2 Despite our ﬁndings in the short
term, offering ART to TB patients is therefore likely
to have a favourable impact on long-term survival.15
The strengths of this study were that a large num-
ber of TB patients were studied, deaths were reliably
ascertained, the loss to follow-up was low and, as the
data come from a programme setting, the ﬁndings re-
flect the operational reality on the ground. There were,
however, also a number of limitations. 1) Although
there were two cohorts of TB patients, those taking
ART were self-selected, and hence the comparison is
not between two equal cohorts; a randomised con-
trolled trial design would have been preferred, but
this was not ethically possible. 2) Despite the fact that
all HIV-positive TB patients are potentially eligible for
ART in our setting, only 27% (about 1 in 3) actually
took up the offer; there are several possible reasons
for this relatively low acceptance rate and these have
been discussed previously.15,16 3) Potential differences
in social or economic status between those who ac-
cepted ART and those who did not might have had an
inﬂuence on case fatality, but we do not have data in
this regard. 4) Baseline CD4-lymphocyte counts were
not recorded, and we therefore do not know if there
were any immunological differences between the
groups; however, the proportion of patients by ‘type
of TB’ (likely to be a proxy of immune status) was
similar between those who did and those who did not
accept ART.
Reducing high early case-fatality rates during anti-
tuberculosis treatment in sub-Saharan Africa contin-
ues to be a major challenge. There are several poten-
tial reasons for early deaths among patients with TB:
for example, delayed presentation of patients and thus
advanced TB and HIV/AIDS, late diagnosis of TB
within health services, life-threatening HIV-related
complications such as anaemia and bacteraemia,17,18
the occurrence of a Herxheimer-type reaction (para-
doxical reaction) due to rapid killing of tubercle bacilli
by anti-tuberculosis drugs or immune reconstitution.19
In rural settings such as Thyolo, moderate to severe
malnutrition, perhaps by further compromising host
immunity and predisposing to life-threatening nutri-
tional deﬁciencies and superadded infection, adds to
the risk of death.20 More recently, multi- and extremely
drug-resistant TB have been shown to be associated
with high case fatality in South Africa,21 and we do
not know as yet if this is also a problem in Malawi.
There are a number of possible ways of addressing
the problem of high early case fatality. First, increas-
ing community awareness, improving health seeking
behaviour linked to HIV/AIDS and TB, and address-
ing access issues in terms of both diagnosis and treat-
ment might prevent patients from presenting ‘too late’.
Second, efforts need to be made to reduce diagnostic
Figure 3 Survival probability in relation to ART during the con-
tinuation phase (months 2–8) of anti-tuberculosis treatment,
Thyolo, Malawi. HIV   human immunodeﬁciency virus; TB  
tuberculosis; ART   antiretroviral treatment.852 The International Journal of Tuberculosis and Lung Disease
and treatment delays linked to smear-negative PTB
and EPTB by introducing the recently recommended
standardised diagnostic and treatment algorithms.22
This does not, however, replace the urgent need for
access to simpler and more efﬁcient TB diagnostic
tools for use in resource-limited settings. Third, iden-
tiﬁcation of bacteraemia in many African hospitals is
very difﬁcult because of a lack of access to blood cul-
ture facilities, and HIV-positive TB patients might need
to be offered an empirical course of broad spectrum
antibiotics to treat commonly occurring but poten-
tially lethal infections due to Streptococcus pneumo-
niae and non-typhoidal Salmonella.17,18 Fourth, corti-
costeroids have been suggested as one way of reducing
early deaths due to Herxheimer-type reactions by re-
ducing the toxicity of the disease.19 Prospective con-
trolled trials have shown a treatment beneﬁt of corti-
costeroids in TB meningitis and pericardial and pleural
disease.23 However, trials on the use of corticoster-
oids, particularly in ill HIV-positive TB patients, have
yet to be carried out and published, but they might be
warranted. Fifth, intensive nutritional rehabilitation
and use of micronutrients among malnourished TB
patients by improving cell-mediated and humoral im-
munity might be of beneﬁt. Finally, there is the ques-
tion of the optimal time to start ART in HIV-positive
TB patients. This study clearly identiﬁed the ﬁrst
2 months of TB treatment as the time of greatest mor-
tality. Starting ART earlier, particularly with EFV-based
regimens, would seem to be an option that needs se-
rious attention. Its impact on morbidity and mortal-
ity and issues related to co-management needs to be
studied further in an operational setting. The associ-
ated risks might include additive adverse drug reac-
tions, drug-drug interactions and a higher incidence
of immune reconstitution disease.24
The ﬁndings from this study provide ample ground
for discussion and most of all the much needed impetus
to urgently address the issue of high early case fatality
in TB patients through relevant interventions and op-
erational research while waiting for the results of ran-
domised controlled trials.
The results of this study also highlight the urgent
need to improve TB-HIV co-management and better
collaboration between TB and HIV programmes.
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RÉSUMÉ
CADRE : District de Thyolo, Malawi.
OBJECTIFS:Faire un rapport sur 1) la létalité chez les
patients tuberculeux (TB) séropositifs pour le VIH au
cours du traitement anti-tuberculeux ; et 2) la question
de la réduction de la létalité par la mise en route du
traitement antirétroviral (ART) au cours de la phase de
continuation du traitement TB.
SCHÉMA :Analyse rétrospective de cohorte.
METHODS:Analyse comparative des résultats du traite-
ment chez les patients TB enregistrés entre janvier et
décembre 2004.
RÉSULTATS: Sur 983 nouveaux cas de TB enregistrés
ayant bénéficié d’un test VIH, 658 (67%) étaient séro-
positifs pour le VIH. Au total 132 patients (20%) sont
décédés au cours des 8 mois du traitement antituber-
culeux, parmi lesquels 82 (62%) sont décédés au cours
des 2 premiers mois du traitement en l’absence d’ART
(incidence cumulative   3,0 ; IC95% 2,5–3,6 pour 100
années-personne). La phase de continuation du traite-
ment anti-tuberculeux a été démarrée chez 576 patients
TB, dont 180 (31%) ont reçu l’ART. Le taux de létalité
par 100 années-personne n’a pas été significativement
différent entre les patients sous ART (1,0 ; IC95% 0,6–
1,7) et sans ART (1,2 ; IC95% 0,9–1,7 ; risque relatif
ajusté 0,86 ; IC95% 0,4–1,6 ; P   0.6).
CONCLUSIONS:L’administration d’ART pendant la phase
de continuation du traitement anti-tuberculeux n’a pas
un impact significatif sur la réduction de la létalité. Les
raisons de ce fait et les mesures possibles pour réduire la
létalité élevée dans la phase initiale du traitement TB
font l’objet de la discussion.
RESUMEN
MARCO DE REFERENCIA: Distrito de Thyolo, Malawi.
OBJETIVOS:Comunicar sobre 1) la mortalidad de los
pacientes con tuberculosis (TB) e infección por el VIH
durante el tratamiento antituberculoso ; y 2) el efecto del
tratamiento antirretrovírico (ART) durante la fase de
continuación del tratamiento antituberculoso en térmi-
nos de reducción de la mortalidad.
DESEÑO :Estudio retrospectivo de cohortes.
MÉTODOS:Análisis comparativo del desenlace terapéu-
tico de pacientes con TB registrados entre enero y di-
ciembre de 2004.
RESULTADOS:Se registraron 983 casos nuevos de TB,
todos recibieron la prueba diagnóstica de la infección
por el VIH y en 658 (67%) el resultado fue positivo.
Un total de 132 pacientes (20%) falleció durante los
8 meses del tratamiento antituberculoso, de los cuales
82 (62%) en los primeros 2 meses, antes de comenzar la
administración del ART (incidencia acumulada 3,0/100
años-persona ; IC95% 2,5–3,6). De los 576 pacientes
con TB que comenzaron la fase de consolidación del
tratamiento antituberculoso, 180 (31%) iniciaron tam-
bién el ART. La diferencia de la tasa de mortalidad por
100 años-persona entre los pacientes con ART (1,0 ;
IC95% 0,6–1,7) y sin él (1,2 ; IC95% 0,9–1,7) no fue es-
tadísticamente significativa (cociente ajustado de riesgos
instantáneos 0,86 ; IC95% 0,4–1,6 ; P   0,6).
CONCLUSIONES:El ART suministrado en la fase de con-
tinuación del tratamiento antituberculoso no tuvo un
efecto significativo sobre la reducción de la mortalidad.
En el artículo se comentan las razones de este resultado y
las medidas que podrían reducir la alta tasa de mortali-
dad durante la fase inicial del tratamiento antituberculoso.